NCT00091026View on ClinicalTrials.gov

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
Interventions
BIOLOGICAL

cetuximab

Given IV

DRUG

gemcitabine hydrochloride

Given IV

BIOLOGICAL

bevacizumab

Given IV

DRUG

erlotinib hydrochloride

Given orally

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00091026 - Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter